Composition : Ofloxacin 200mg + Nitazoxanide 500mg Tablet
`Ofloxacin Nitazoxanide Tablet (OFLORIV-NZ)
In the modern age of antimicrobial resistance and complex infections, mono-therapy often falls short. To meet the evolving challenges of gastrointestinal and mixed microbial infections, Fedley Healthcare introduces OFLORIV-NZ, a dynamic dual-action tablet combining Ofloxacin 200 mg and Nitazoxanide 500 mg. This scientifically optimized combination delivers a synergistic punch against both bacterial and protozoal infections, ensuring quick relief and complete recovery.
As a trusted name in pharmaceuticals, Fedley Healthcare is proud to expand its antimicrobial portfolio with this power-packed combination, reflecting our ethos—Precision in Formulation, Compassion in Healing.
Each film-coated tablet of OFLORIV-NZ is formulated to provide superior bioavailability, excellent tolerability, and effective multi-pathogen control.
A 2nd-generation fluoroquinolone, Ofloxacin inhibits DNA gyrase and topoisomerase IV, key enzymes involved in bacterial DNA replication. It is highly effective against Gram-positive and Gram-negative bacteria and remains a go-to choice in various systemic infections.
Nitazoxanide, a thiazolide class drug, works through interference with the pyruvate:ferredoxin oxidoreductase enzyme-dependent electron transfer reaction, essential for anaerobic energy metabolism. It acts on protozoa (e.g., Giardia, Entamoeba), helminths, and even viral infections like rotavirus and norovirus.
OFLORIV-NZ is ideal for gastrointestinal and systemic infections involving mixed pathogens. Key indications include:
OFLORIV-NZ is generally well tolerated. Mild side effects may include:
At Fedley Healthcare, each product is a promise—crafted with GMP-WHO certified manufacturing and a rigorous QA/QC pipeline to ensure every dose is consistent, safe, and effective.
With OFLORIV-NZ, we are addressing a critical therapeutic gap in developing and tropical regions where mixed gastrointestinal infections are common, yet poorly managed.
We’re not just offering OFLORIV-NZ—we’re offering an opportunity. Join one of India’s fastest-growing ethical pharma brands and launch your own pharma business with Fedley Healthcare’s PCD Pharma Franchise Model.
High-Profit Margins
Monopoly Rights (Territory-Wise)
Attractive Promotional Inputs – MR bags, visual aids, samples, brochures
Timely Dispatch & Transparent Pricing
Wide Product Portfolio – Covering antibiotics, antivirals, nutraceuticals, pain management, and more
Dedicated Franchise Support Team
Fedley Healthcare invites motivated partners from all across India to become part of our growing franchise network. We believe in mutual growth and shared vision—where your success is our achievement.
Whether you're entering the pharmaceutical business for the first time or expanding your current portfolio, OFLORIV-NZ and our diverse range of formulations are ideal starting points.
OFLORIV-NZ by Fedley Healthcare is not just a tablet—it’s next-gen gastrointestinal therapy. With the dual action of Ofloxacin and Nitazoxanide, we bring a scientifically validated, patient-friendly, and cost-effective solution to frontline healthcare professionals.
Fedley Healthcare is proud to provide this potent combination to clinics, hospitals, pharmacies, and healthcare providers across India.